Lys Therapeutics
Created in 2021
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
3,042Activities
Technologies
Entity types
Location
56 Rue Saint-Jean-de-Dieu, 69007 Lyon, France
Lyon
France
Employees
Scale: 11-50
Estimated: 12
SIREN
895069904Engaged corporates
20
5 14Added in Motherbase
1 year, 7 months ago
biotech Value proposition
First-in-class biotherapies against neurological diseases.
Targeting neuroinflammation to tackle neurodegeneration.
Lys Therapeutics is a pioneering biotechnology company revolutionizing the treatment of patients with neurodegenerative or neurovascular diseases by targeting blood-brain barrier (BBB) dysfunctions and neuroinflammation.
In the pathophysiology of various neurological diseases such as stroke, multiple sclerosis, and Parkinson's disease, the hyperactivation of endothelial NMDA receptors (NMDAr) by tissue plasminogen activator (tPA) overexpressed in these patients leads to the degradation of tight junctions and BBB dysfunction, allowing the transmigration of inflammatory cells and toxic molecules into the brain parenchyma, triggering excitotoxicity and neuroinflammation, major contributors to neurodegeneration.
Lys Therapeutics' lead drug candidate, LYS241, is a first-in-class monoclonal antibody with a unique mechanism of action that effectively counteracts these pathological mechanisms. Specifically, LYS241 acts in blood vessels to prevent the binding of tPA to NMDAr without interfering with the physiological function of NMDAr. By inhibiting this interaction, NMDAr can function normally, and the activation of deleterious downstream cellular pathways is stopped. Tight junctions are restored, endothelial cells return to their healthy state, and BBB function is restored, protecting the brain from neuroinflammatory and neurodegenerative cascades.
Lys Therapeutics' approach to targeting neuroinflammation to combat neurodegeneration represents a promising pathway in the quest for effective treatments for these debilitating disorders.
Stroke, Multiple Sclerosis, Neurology, Neurodegenerative disorders, Healthcare, Biotechnology, Pharma, Drug development, Antibody, Parkinson, Parkinson's Disease, and Neurovascular diseasesOriginal language
First-in-class biotherapies against neurological diseases.
Targeting neuroinflammation to tackle neurodegeneration.
Lys Therapeutics is a pioneering biotechnology company revolutionizing the treatment of patients with neurodegenerative or neurovascular diseases by targeting blood-brain barrier (BBB) dysfunctions and neuroinflammation.
In the pathophysiology of various neurological diseases such as stroke, multiple sclerosis, and Parkinson's disease, the hyperactivation of endothelial NMDA receptors (NMDAr) by tissue plasminogen activator (tPA) overexpressed in these patients leads to the degradation of tight junctions and BBB dysfunction, allowing the transmigration of inflammatory cells and toxic molecules into the brain parenchyma, triggering excitotoxicity and neuroinflammation, major contributors to neurodegeneration.
Lys Therapeutics' lead drug candidate, LYS241, is a first-in-class monoclonal antibody with a unique mechanism of action that effectively counteracts these pathological mechanisms. Specifically, LYS241 acts in blood vessels to prevent the binding of tPA to NMDAr without interfering with the physiological function of NMDAr. By inhibiting this interaction, NMDAr can function normally, and the activation of deleterious downstream cellular pathways is stopped. Tight junctions are restored, endothelial cells return to their healthy state, and BBB function is restored, protecting the brain from neuroinflammatory and neurodegenerative cascades.
Lys Therapeutics' approach to targeting neuroinflammation to combat neurodegeneration represents a promising pathway in the quest for effective treatments for these debilitating disorders.
Home - Lys Therapeutics
Lys Therapeutics, first-in-class biotherapies against neurological diseases
https://lystherapeutics.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 MEDICALPS Business Consulting and Services | MEDICALPS Business Consulting and Services | Other 22 Jan 2024 | | |
 Ouest-France Media, Newspaper Publishing | Ouest-France Media, Newspaper Publishing | Other 20 Nov 2023 | | |
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 25 Oct 2024 | | |
 Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Other 25 Oct 2024 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 25 Sep 2024 | | |
 Pôle TES Public business cluster, French Cluster, Business Consulting and Services | Pôle TES Public business cluster, French Cluster, Business Consulting and Services | Other 24 Sep 2023 | | |
 Société des Neurosciences NGO, Think Tank, Civic and Social Organizations | Société des Neurosciences NGO, Think Tank, Civic and Social Organizations | Other 26 May 2023 | | |
 Roche Pharmaceutical, Biotechnology, Biotechnology Research | Roche Pharmaceutical, Biotechnology, Biotechnology Research | Other 10 Oct 2023 | | |
 Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Other 10 Oct 2023 | | |
 French Tech Normandie Caen French Tech, IT Services and IT Consulting | French Tech Normandie Caen French Tech, IT Services and IT Consulting | Other 20 Mar 2023 | | |